{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:56:42Z","timestamp":1791475002095,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.mayocp.2019.05.031","type":"journal-article","created":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T06:59:22Z","timestamp":1570949962000},"page":"2220-2229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8406-7744","authenticated-orcid":false,"given":"Yao","family":"Qiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Im","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley A.","family":"Inker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Secora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Coresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Caleb","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex R.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4430-6023","authenticated-orcid":false,"given":"Morgan E.","family":"Grams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.mayocp.2019.05.031_bib1","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.mayocp.2019.05.031_bib2","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1097\/00004872-200110000-00023","article-title":"A\u00a0random comparison of fosinopril and nifedipine GITS in patients with primary renal disease","volume":"19","author":"Marin","year":"2001","journal-title":"J\u00a0Hypertens"},{"issue":"12","key":"10.1016\/j.mayocp.2019.05.031_bib3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2019.05.031_bib4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/pds.3941","article-title":"The effect of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker use on mortality in patients with chronic kidney disease: a meta-analysis of observational studies","volume":"25","author":"Qin","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"21","key":"10.1016\/j.mayocp.2019.05.031_bib5","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.mayocp.2019.05.031_bib6","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s12325-018-0697-x","article-title":"Efficacy and safety of zofenopril versus ramipril in the treatment of myocardial infarction and heart failure: a review of the published and unpublished data of the randomized double-blind SMILE-4 Study","volume":"35","author":"Borghi","year":"2018","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.mayocp.2019.05.031_bib7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJM199501123320203","article-title":"The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators","volume":"332","author":"Ambrosioni","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2019.05.031_bib8","doi-asserted-by":"crossref","first-page":"445.e7","DOI":"10.1016\/j.ahj.2006.12.005","article-title":"Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study","volume":"153","author":"Borghi","year":"2007","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.mayocp.2019.05.031_bib9","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0735-1097(98)00609-3","article-title":"Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials","volume":"33","author":"Domanski","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.mayocp.2019.05.031_bib10","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.mayocp.2019.05.031_bib11","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.mayocp.2019.05.031_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078465","article-title":"ACE inhibitor and angiotensin receptor-II antagonist prescribing and hospital admissions with acute kidney injury: a longitudinal ecological study","volume":"8","author":"Tomlinson","year":"2013","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.mayocp.2019.05.031_bib13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000013599","article-title":"Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors","volume":"20","author":"Ahuja","year":"2000","journal-title":"Am J Nephrol"},{"issue":"3","key":"10.1016\/j.mayocp.2019.05.031_bib14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000447068","article-title":"Should we stop angiotensin converting enzyme inhibitors\/angiotensin receptor blockers in advanced kidney disease?","volume":"133","author":"Ahmed","year":"2016","journal-title":"Nephron"},{"issue":"2","key":"10.1016\/j.mayocp.2019.05.031_bib15","first-page":"255","article-title":"Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial","volume":"31","author":"Bhandari","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.mayocp.2019.05.031_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.mayocp.2015.10.019","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials","volume":"91","author":"Bangalore","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.mayocp.2019.05.031_bib18","first-page":"1181","article-title":"Antihypertensive medications and the prevalence of hyperkalemia in a large health system","volume":"67","author":"Chang","year":"2016","journal-title":"Hypertens Dallas Tex 1979"},{"issue":"9","key":"10.1016\/j.mayocp.2019.05.031_bib19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"446","key":"10.1016\/j.mayocp.2019.05.031_bib20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"9","key":"10.1016\/j.mayocp.2019.05.031_bib21","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1097\/01.ASN.0000135969.33773.0B","article-title":"\u201cRenalism\u201d: inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency","volume":"15","author":"Chertow","year":"2004","journal-title":"J\u00a0Am Soc Nephrol JASN"},{"issue":"11","key":"10.1016\/j.mayocp.2019.05.031_bib22","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.2215\/CJN.09430914","article-title":"AKI and medical care after coronary angiography: renalism revisited","volume":"9","author":"Weisbord","year":"2014","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"10","key":"10.1016\/j.mayocp.2019.05.031_bib23","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/bcp.13692","article-title":"Prescription patterns of angiotensin-converting enzyme inhibitors for various indications: A UK population-based study","volume":"84","author":"Mahmoudpour","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"13","key":"10.1016\/j.mayocp.2019.05.031_bib24","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jacc.2018.01.058","article-title":"Angiotensin-converting enzyme inhibitors in hypertension: To use or not to use?","volume":"71","author":"Messerli","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.mayocp.2019.05.031_bib25","first-page":"195","article-title":"The diuretic dilemma and the management of mild hypertension","volume":"2","author":"Moser","year":"1986","journal-title":"J\u00a0Clin Hypertens"},{"issue":"6","key":"10.1016\/j.mayocp.2019.05.031_bib26","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jash.2013.05.004","article-title":"Effects of low-dose thiazide diuretics on fasting plasma glucose and serum potassium-a meta-analysis","volume":"7","author":"Mukete","year":"2013","journal-title":"J\u00a0Am Soc Hypertens JASH"},{"issue":"10","key":"10.1016\/j.mayocp.2019.05.031_bib27","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/ajh\/hpw030","article-title":"Diuretics for hypertension: a review and update","volume":"29","author":"Roush","year":"2016","journal-title":"Am J Hypertens"},{"issue":"7","key":"10.1016\/j.mayocp.2019.05.031_bib28","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/archinte.158.7.741","volume":"158","author":"Savage","year":"1998","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.mayocp.2019.05.031_bib29","first-page":"1041","article-title":"Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects","volume":"65","author":"Roush","year":"2015","journal-title":"Hypertens Dallas Tex 1979"},{"issue":"6","key":"10.1016\/j.mayocp.2019.05.031_bib30","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/ki.1985.229","article-title":"Diuretic-induced hypokalemia","volume":"28","author":"Tannen","year":"1985","journal-title":"Kidney Int"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619305804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619305804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:30:59Z","timestamp":1758418259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619619305804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0025619619305804"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.05.031","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.05.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}